| Pletal Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Pletal 50 mg | tablet | oral | 1.0 each | OTC |
| Pletal 100 mg | tablet | oral | 1.0 each | OTC |
Posted by jckey2 over 2 years ago
After taking just 1 a day after 4 days , 2 hrs later I had chest palpatations for 20 min. I talked with the druggist and she said it takes a few days to get use to it. Now it has been a week and no trouble.It does help the tightness in the toes and around the ankle.
Posted by psalty over 5 years ago
I have taken two Pletal as directed..one last evening on an empty stomach and one this morning on an empty stomach. This afternoon "Suddenly" I was HIT with diarrhea out in public..NO warning. Again and again before I could get home to change clothes..and then a headache. I have a painful, swollen stomach, headache and will not be taking anymore pletal for my sjogrens symptoms (cold, numb hands and feet).
Posted by jane over 5 years ago
Is pletal to be taken with or without food?
Learn about the perspectives for Peripheral artery disease - Poor ... - PharmaLive.com (press release)
Cilostazol (Pletal), an antiplatelet, is recommended as first-line therapy for claudication The new agents in development for PAD are primarily as secondary ...
Fri Feb 08 07:38:38 +0000 2008
Evaluate Therapies under Development for Peripheral Artery Disease ... - Business Wire (press release)
Cilostazol (Pletal), an antiplatelet, is recommended as first-line therapy for claudication The new agents in development for PAD are primarily as secondary ...
Wed Feb 06 04:58:59 +0000 2008
OrthoLogic: The Wall Street Analyst Forum Presentation Transcript - Seeking Alpha
Four key agents that you are hopefully familiar with on the slide, Natrecor indicated for congestive heart failure, Pletal for intermediate claudication, ...
Thu Sep 20 16:00:31 +0000 2007
cilostazol - A quinolinone derivative and cellular phosphodiesterase inhibitor, more specific for phosphodiesterase III (PDE III). Although the exact mechanism of action of is unknown, cilostazol and its metabolites appears to inhibit PDE III activity, thereby suppressing cyclic adenosine monophosphate (cAMP) degradation. This results in an increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation.